FDA expands Sprycel approval to include certain children with acute lymphoblastic leukemia
- OPACC
- Jan 3, 2019
- 1 min read
The FDA expanded the approval of dasatinib tablets to include its use with chemotherapy for children aged 1 year or older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Commentaires